Randomized Controlled Trial Evaluating Threshold Sound Conditioning in the treatment of Sensorineural Hearing Loss (S26.006)
Citation Manager Formats
Make Comment
See Comments

Abstract
OBJECTIVE: To evaluate safety and efficacy of threshold sound conditioning (TSC) as possible treatment for sensorineural hearing loss. BACKGROUND: Sensorineural hearing loss, an irreversible phenomenon, is one of the most common human disorders, with increasing incidence in elderly patients, severely restricting normal activities and lowering quality of life. However, there are data for central neuronal plasticity and potential for recovery. The introduction of sound conditioning has the potential to activate auditory pathway plasticity and improve basal frequency hearing as measured by pure tone audiometry (PTA). DESIGN/METHODS: Double-blind, randomized, placebo controlled trial of 42 subjects . Data were analyzed using an intention-to-treat design. PTA was performed and hearing thresholds were measured at 8~9 frequencies (0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 KHz) in both ears of each subject, once at baseline, and a second time following TSC intervention. Subjects used a TSC conditioning-enhanced hearing aid 1 hour per day at the hearing threshold level, for 2~3 weeks. RESULTS: Seventy-eight percent of the TSC group showed a significant difference from 44[percnt] in the control group on auditory threshold amelioration; p=0.008091 using ameliorated or mixed change as the dependent variable; and p=0.000546 using ameliorated and mixed combined as a dependent variable by Scheffe’s post hoc test. 77[percnt] of female subjects showed a significant difference in dependent variables from the 47[percnt] of the male subjects; p=0.025468. 75[percnt] of older subjects showed no significant difference from 53[percnt] of the younger subjects; p=0.139149. CONCLUSIONS: TSC outputs an algorithmic acoustic signal with a preset intensity to the frequency band of the damaged hair cell. Previously published human data, and this prospective clinical study demonstrate a statistically significant improvement in a narrow band frequency threshold. These data have important clinical implications as a potential long term therapy for this widespread and growing disability.
Disclosure: Dr. Cho has nothing to disclose. Dr. Kwak has nothing to disclose. Dr. Kwak has nothing to disclose. Dr. Lopez has received research support from Earlogic/The Good Ear Company.
Wednesday, April 22 2015, 2:00 pm-3:45 pm
- Copyright © 2015 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.